• Author Archives: ino_admin

    Preclinical work on INS-3001 efficacy in renal fibrosis published

    We are glad to share that our latest preclinical work studying the efficacy of INS-3001 in the context of phosphate-induced renal fibrosis has been published in ACS Pharmacology & Translational Science.

    Posted in News | Leave a comment

    Inositec Appoints Serial Entrepreneur and Cardiologist Michael H. Davidson to Board of Directors

    Zurich, Switzerland, October 7, 2020 – Inositec, a pioneer in the development of life-saving small molecule drugs for calcification disorders such as aortic valve stenosis, announced today that Michael H. Davidson, MD, has been appointed to the Board of Directors. … Continue reading

    Posted in Press Release | Leave a comment

    Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001

    Zurich, Switzerland, May 4, 2020 – Inositec, a pioneer in the development of life-saving small molecule drugs based on the natural compound inositol hexaphosphate (IP6), announced today that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering … Continue reading

    Posted in Press Release | Leave a comment

    Preclinical work on calcium oxalate inhibitors for renal indications published

    We are thrilled to have published data in Advanced Science that further validates the therapeutic potential of IP6 analogs from Inositec’s InosituneTM platform in calcification disorders, here in the context of calcium oxalate crystal-related diseases. Calcium oxalate is the most … Continue reading

    Posted in News | Leave a comment

    Inositec’s INS-3001 Significantly Reduces Cardiovascular Calcification in Proof-of-Concept Studies Published in Nature Communications

    Zurich, Switzerland, February 5, 2020 – Inositec, a pioneer in the development of life-saving small molecule drugs based on myo-inositol hexaphosphate (IP6), announced today that positive proof-of-concept data on INS-3001, a novel cardiovascular calcification inhibitor, were published in Nature Communications … Continue reading

    Posted in Press Release | Leave a comment

    Discovery work on Clostridium difficile toxin inhibitors published

    The early work on the rational design of Clostridium difficile toxin inhibitors based on inositol hexaphosphate analogs has been published in Cell Chemical Biology. Our Clostridium difficile inhibitors are available for partnering and we are happy to discuss further details with interested parties. Please … Continue reading

    Posted in News | Leave a comment

    Inositec’s INS-3001 Significantly Reduces Vascular Calcification Data Presented at Kidney Week 2018 Indicates

    Zurich, Switzerland, 26 October 2018 – Inositec, a pioneer in the development of life-saving small molecule drugs based on myo-inositol hexaphosphate (IP6), announced today that INS-3001, a novel vascular calcification inhibitor, demonstrated the ability to significantly inhibit the calcification process … Continue reading

    Posted in Press Release | Leave a comment

    Inositec AG Appoints Dr Frits van Alphen as Chief Medical Officer

    Zurich, Switzerland, 18 January 2018 – Inositec, a pioneer in the development of life-saving small molecule drugs based on inositol hexaphosphate (IP6), announced today the appointment of Frits van Alphen, MD, as Chief Medical Officer. Dr van Alphen has over … Continue reading

    Posted in Press Release | Leave a comment

    Inositec wins Swiss Technology Award 2017

    We are proud to have won the Swiss Technology Award 2017. More information here (German).

    Posted in News | Leave a comment

    Inositec featured in BioCentury

    BioCentury is featuring Inositec in this week’s emerging company profile. Read the article here (requires subscription).

    Posted in News | Leave a comment